Wegovy Heart Palpitations: FDA Label, STEP-1 and SELECT Evidence Review

The honest answer: Wegovy (semaglutide 2.4 mg) raises mean resting heart rate by 1 to 4 bpm and the FDA label Section 5.9 instructs prescribers to tell patients to report palpitations or a racing heartbeat at rest. Palpitations are not a ≥2% labeled adverse reaction, but they are a labeled clinical-monitoring concern. The 2023 SELECT trial showed semaglutide reduced major adverse cardiovascular events by 20% over 39.8 months — meaning the small HR rise does not translate into cardiovascular harm at the population level.

At a glance

• Wegovy label Section 5.9 (revised May 2026): mean resting HR increase of 1 to 4 bpm vs placebo^[1]
• 26% of Wegovy adults had a peak HR rise of ≥20 bpm at some visit vs 16% on placebo^[1]
• Label instruction: “Monitor heart rate at regular intervals consistent with usual clinical practice. Instruct patients to inform their healthcare providers of palpitations or feelings of a racing heartbeat while at rest during WEGOVY treatment.”^[1]
• Discontinuation guidance: “If patients experience a sustained increase in resting heart rate, discontinue WEGOVY.”^[1]
• SELECT cardiovascular outcomes trial (n=17,604, 39.8 months): 20% relative reduction in major adverse cardiovascular events on semaglutide vs placebo^[3]
• Wegovy thorough-QTc trial: no QT prolongation at semaglutide doses up to 1.5 mg^[1]
• Class effect: liraglutide, dulaglutide, and semaglutide all raise resting HR by 2 to 5 bpm; the magnitude is consistent across the GLP-1 class^[6]

What “heart palpitations on Wegovy” usually looks like

Patients searching this phrase typically describe one of three patterns:

1. Awareness of the heartbeat at rest — most often felt lying down, especially in the evening or at sleep onset. Pulse counted manually is in the 80-100 bpm range — higher than personal baseline but not technically tachycardic.
2. Brief fluttering or skipped-beat sensations lasting seconds to a minute, often a few times per day during titration weeks. These are usually premature atrial or ventricular complexes (PACs / PVCs), benign in structurally normal hearts.
3. Sustained rapid heartbeat with chest awareness — resting pulse persistently 100-120 bpm. This is the pattern the Wegovy label Section 5.9 specifically wants the prescriber to know about, and the label instructs discontinuation if the resting increase is sustained.

Pattern 1 and 2 are common and usually self-limited as the body adjusts during titration. Pattern 3 warrants a prescriber call and often an ECG.

What the Wegovy FDA label §5.9 says, verbatim

From the Wegovy package insert revised May 2026^[1]:

“Treatment with WEGOVY was associated with increases in resting heart rate. Mean increases in resting heart rate of 1 to 4 beats per minute (bpm) were observed in WEGOVY injection-treated adult patients compared to placebo in clinical trials for weight reduction. More adult patients treated with WEGOVY injection compared with placebo had maximum changes from baseline at any visit of 10 to 19 bpm (41% versus 34%, respectively) and 20 bpm or more (26% versus 16%, respectively). In a clinical trial in pediatric patients aged 12 years and older with normal baseline heart rate, more patients treated with WEGOVY injection compared to placebo had maximum changes in heart rate of 20 bpm or more (54% versus 39%). Findings were similar in a trial with the WEGOVY tablets.”

“Monitor heart rate at regular intervals consistent with usual clinical practice. Instruct patients to inform their healthcare providers of palpitations or feelings of a racing heartbeat while at rest during WEGOVY treatment. If patients experience a sustained increase in resting heart rate, discontinue WEGOVY.”

Two things to notice. First, the label does not call this rare — 41% of treated adults had at least one visit with a 10-19 bpm rise from baseline. Second, the discontinuation instruction is specific tosustained increase, not to a single high reading.

What §6.1 Adverse Reactions does and doesn't list

Section 6.1 of the Wegovy label lists adverse reactions reported in ≥2% of treated patients and more often than placebo across the STEP-1, STEP-3, and STEP-5 pooled safety database (n=2,116 on Wegovy 2.4 mg). The dominant entries are gastrointestinal: nausea (44% vs 16%), diarrhea (30% vs 16%), vomiting (24% vs 6%), constipation (24% vs 11%), abdominal pain (20% vs 10%).

Tachycardia and palpitations are not listed as discrete ≥2% adverse reactions in the Section 6.1 table. The heart-rate signal lives in the Section 5.9 Warnings and Precautions block as a population-level mean change, not as a symptom-coded adverse reaction. This is an important distinction: it means most patients do not experience the HR increase as a symptom.

What STEP-1 reported about heart rate

STEP-1 (Wilding et al. NEJM 2021)^[2] randomized 1,961 adults with obesity (BMI ≥30, or ≥27 with at least one weight-related comorbidity) to semaglutide 2.4 mg or placebo over 68 weeks, on top of lifestyle counseling. The primary efficacy outcome was the percentage change in body weight: −14.9% on semaglutide vs −2.4% on placebo.

For heart rate specifically, the mean change from baseline at week 68 was approximately +3 bpm on semaglutide vs roughly no change on placebo. The Wegovy label-rolled figure (mean increase of 1 to 4 bpm) integrates STEP-1, STEP-3 (semaglutide plus intensive behavioral therapy), and STEP-5 (104-week extension), which is why the label cites a range rather than a single STEP-1 number.

STEP-2 (Davies et al. Lancet 2021)^[4] tested semaglutide 2.4 mg in adults with type 2 diabetes and obesity (n=1,210). HR increases of similar magnitude were observed — the small mean rise on semaglutide is consistent whether the population has diabetes or not.

What SELECT showed about cardiovascular outcomes long-term

The cardiovascular concern with a 1-to-4 bpm HR rise is whether it accumulates into actual harm — more arrhythmias, more heart failure, more cardiovascular death. SELECT (Lincoff et al. NEJM 2023)^[3] is the trial that answers that question.

SELECT randomized 17,604 adults with obesity (BMI ≥27) and pre-existing cardiovascular disease but no diabetes to semaglutide 2.4 mg vs placebo. Mean follow-up was 39.8 months. Headline results:

• 20% relative reduction in the primary composite (cardiovascular death, non-fatal MI, non-fatal stroke): HR 0.80, 95% CI 0.72-0.90
• 15% relative reduction in cardiovascular death (HR 0.85, 95% CI 0.71-1.01) — directionally consistent but did not reach statistical significance on its own
• 19% reduction in heart failure hospitalization
• No excess in serious arrhythmia events vs placebo over 39.8 months

On the strength of SELECT, the FDA added a labeled cardiovascular benefit indication to Wegovy in 2024 — the first weight-loss drug to carry formal cardiovascular outcome labeling. The implication for the palpitations question: across 17,604 patients followed for over three years, the labeled resting-HR increase did not translate into excess cardiovascular harm. The opposite was true.

This does not mean palpitations should be ignored individually. It means the population-level signal does not support stopping Wegovy broadly on cardiac safety grounds.

The older GLP-1 outcomes data: SUSTAIN-6 and the class

SUSTAIN-6 (Marso et al. NEJM 2016)^[5] tested once-weekly semaglutide at the diabetes doses (0.5 mg and 1.0 mg) in 3,297 adults with type 2 diabetes and high CV risk. Median follow-up 2.1 years. Primary composite (CV death, non-fatal MI, non-fatal stroke): HR 0.74, 95% CI 0.58-0.95 — a 26% relative reduction, statistically significant. Heart-rate increase of approximately +2.5 bpm on semaglutide; no excess in arrhythmia or sudden death.

The Lorenz 2017 cross-trial analysis^[6] compared HR effects across the GLP-1 class. Short-acting GLP-1s (lixisenatide, exenatide twice-daily) raised resting HR by approximately 1-2 bpm; long-acting GLP-1s (liraglutide, dulaglutide, exenatide LAR, semaglutide) raised it by 2-5 bpm. The mechanism is shared across the class.

Mechanism — why GLP-1s raise heart rate

Three mechanisms have been proposed; none on its own fully explains the effect, and all may contribute:

1. Direct sinoatrial node action. GLP-1 receptors are expressed in the human sinoatrial node. Activation increases the intrinsic firing rate of the pacemaker cells, raising heart rate independent of any reflex or systemic effect.
2. Reduced parasympathetic (vagal) tone. GLP-1 receptor activation may attenuate baroreflex-mediated vagal slowing of the heart, leaving the sympathetic input relatively unopposed.
3. Modest sympathetic activation. Some animal and human autonomic studies suggest a small increase in sympathetic outflow with GLP-1 receptor activation, though the data are mixed.

Practically: the effect appears within days of starting or escalating the dose, plateaus by week 12-20, and persists at the maintenance dose without further escalation. It does not progress over time on stable dosing.

When palpitations are a red flag

From the Wegovy Medication Guide^[1]: “Tell your healthcare provider if you feel your heart racing or pounding in your chest and it lasts for several minutes.” Beyond that label-level guidance, the following should prompt urgent or emergency-department evaluation:

• Palpitations with chest pain, especially if radiating to arm, jaw, or back — acute coronary syndrome workup
• Palpitations with syncope or near-syncope(fainting, almost-fainting, blackout while standing) — arrhythmia workup
• Sustained resting heart rate above 120 bpm (counted manually for a full 60 seconds, twice, several hours apart)
• New irregular heartbeat — pulse that feels chaotic or irregularly irregular rather than fast-but-regular. This pattern can be new-onset atrial fibrillation and warrants an ECG.
• Palpitations with shortness of breath at rest or on minimal exertion, especially if accompanied by leg swelling — heart-failure exacerbation workup
• Focal neurologic symptoms — sudden weakness on one side, slurred speech, vision change, facial droop — these could indicate embolic stroke from a transient AFib episode and warrant emergency-department evaluation

Caffeine, dehydration, and GI losses — common confounders

Before attributing palpitations on Wegovy to the drug itself, audit the confounders. The most common in the first 12 weeks of titration:

• Dehydration. Nausea, vomiting, and diarrhea are the dominant Wegovy adverse reactions (44%, 24%, and 30% in the §6.1 table). Reduced oral intake plus GI losses can produce intravascular volume depletion, which raises resting heart rate reflexively — independent of any direct drug effect on the sinoatrial node.
• Caffeine. 200-400 mg of caffeine (a large drip coffee or two energy drinks) raises resting heart rate by 5-10 bpm in many people, layered on top of the labeled 1-to-4 bpm Wegovy effect.
• Decongestants. Pseudoephedrine (Sudafed) and phenylephrine raise heart rate and blood pressure as a direct sympathomimetic effect.
• ADHD stimulants and phentermine. See our phentermine + GLP-1 article for the combined-cardiovascular-load argument.
• Thyroid-hormone over-replacement. Wegovy increases levothyroxine AUC by 33% in the cited drug-interaction study (see our GLP-1 + levothyroxine interaction guide). If you take levothyroxine, your TSH should be re-checked 4-8 weeks after starting Wegovy and after every dose escalation; new palpitations may be the first sign of relative over-replacement.
• Anxiety and panic. Starting a new medication is a known trigger for somatic-focus anxiety, and palpitations are one of the most-reported anxiety symptoms.

Magnitude — mean resting HR change across GLP-1 trials

Practical takeaway

• A 1-to-4 bpm mean rise in resting heart rate is expected and labeled. It does not, by itself, warrant stopping Wegovy.
• Brief fluttering or awareness of the heartbeat at rest is common during titration and usually settles by week 12-20.
• Monitor at home: count your resting pulse for 60 seconds, first thing in the morning before coffee, twice a week. A baseline-to- maintenance increase of 5-10 bpm is in the labeled range. A sustained resting rate above 100 bpm warrants a prescriber call; above 120 bpm warrants urgent evaluation.
• Audit confounders before assuming the drug: hydration, caffeine, decongestants, thyroid medication, anxiety, stimulants.
• Palpitations with chest pain, syncope, focal neurologic symptoms, or shortness of breath are red flags — call the prescriber the same day or go to the emergency department.
• The 2023 SELECT trial showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% over 39.8 months in patients with obesity and pre-existing cardiovascular disease. The labeled HR increase did not translate into population-level cardiovascular harm.
• Per the label: “If patients experience a sustained increase in resting heart rate, discontinue WEGOVY.” Discontinuation is the prescriber's call, not unilateral.

Related research and tools

• Does a GLP-1 affect blood pressure? Lower, higher, or both — the evidence — the systolic / diastolic companion to this HR review
• SELECT trial: cardiovascular benefits in non-diabetics — the full SELECT cardiovascular outcomes review
• STEP-HFpEF: semaglutide in heart failure — the HFpEF companion
• 17 GLP-1 side effect questions answered — the side-effect Q&A hub
• Can you take phentermine with a GLP-1? — the combined cardiovascular-load argument
• GLP-1 + levothyroxine (Synthroid) interaction — why new palpitations may signal thyroid over-replacement
• GLP-1 side effect timeline tool — when each side effect typically appears and resolves
• GLP-1 drug interaction checker

Important disclaimer. This article is educational and does not constitute medical advice. Decisions to start, continue, or stop Wegovy should always be made with the prescribing clinician. Palpitations with chest pain, syncope, focal neurologic symptoms, or shortness of breath warrant emergency-department evaluation. The Wegovy label Section 5.9 instructs the prescriber to discontinue Wegovy if the patient experiences a sustained increase in resting heart rate — that judgement belongs to the prescriber, not the patient unilaterally.